At Pfizer, A Split A Decade In The Making
Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.
You may also be interested in...
Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup
Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.
A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Merck To Spin Out A New Company, Following Industry's Downsizing Trend
Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.